Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention

Intervirology

Volumn 45, Issue 4-6, 2002, Pages 300-307

  Wakabayashi, Mark T ^a,b   Da Silva, Diane M ^a   Potkul, Ronald K ^b   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Cytotoxic T cell; Human papillomavirus type 16; Vaccine; Virus like particle

Indexed keywords

AMINO ACID; CAPSID PROTEIN; POLYPEPTIDE; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; CANCER PREVENTION; CELLULAR IMMUNITY; CHIMERA; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFICACY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; VACCINE PRODUCTION; VIRUS PARTICLE; WART VIRUS;

ANIMALS; CAPSID; CAPSID PROTEINS; CELL LINE, TRANSFORMED; FEMALE; HUMANS; IMMUNIZATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES; VIRION;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

EID: 0036986254     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067921     Document Type: Conference Paper

References (21)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. Cain JM, Howett MK: Preventing cervical cancer. Science 2000;288:1753-1755.
3. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-12184.
4. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993;67:6929-6936.
5. Hagensee ME, Olson NH, Baker TS, Galloway DA: Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 1994;68:4503-4505.
6. Roden RB, Weissinger EM, Henderson DW, Booy F, Kirnbauer R, Mushinski JF, Lowy DR, Schiller JT: Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol 1994;68:7570-7574.
7. Kawana K, Matsumoto K, Yoshikawa H, Taketani Y, Kawana T, Yoshiike K, Kanda T: A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology 1998;245:353-359.
8. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR: Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-3963.
9. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW: Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-965.
10. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.
11. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-11557.
12. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-292.
13. Müller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L: Chimeric papillomavirus-like particles. Virology 1997;234:93-111.
14. Peng S, Frazer IH, Fernando GJ, Zhou J: Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998;240:147-157.
15. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RBS, Lowy DR, Kast WM, Schiller JT: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998;95:1800-1805.
16. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Müller M, Kast WM: Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 1999;73:145-152.
17. Schafer K, Müller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999;81:881-888.
18. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-26.
19. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249.
20. Mescher MF: Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Immunol Rev 1995;146:177-210.
21. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH: Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000;273:374-382.